As an essential immune-regulated pathway, interferon-alfa (IFN-α) mediated JAK-STAT signaling induces various target genes with antiviral and immunomodulatory functions, based on which IFN-α was used to drive host antiviral responses as the current first-line therapy for chronic hepatitis B and has been confirmed to slow the progression of liver fibrosis and even the emergence of HCC,266 indicating the promising characteristics of this pathway in HCC therapy. This evidence concerns the gene SOAT1 and hepatocellular carcinoma.